Literature DB >> 32691939

Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round-table session.

Christos C Zouboulis1, Wayne Gulliver2,3, John Ingram4, Brian Kirby5, Evangelos J Giamarellos-Bourboulis6, Maurizio Podda7, Thrasyvoulos Tzellos8, Gregor B E Jemec9,10.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32691939     DOI： 10.1111/exd.14123

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


× No keyword cloud information.
  2 in total

Review 1.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

2.  Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.

Authors:  Afsaneh Alavi; Iltefat Hamzavi; Kurt Brown; Leandro L Santos; Zhaoyin Zhu; Huiqing Liu; Michael D Howell; Joslyn S Kirby
Journal:  Br J Dermatol       Date:  2022-03-06       Impact factor: 11.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.